These data suggest that ATRi would be effective in MMRp cells that have increased PD‐L1 expression as a mechanism of overcoming immune evasion and re‐activating the immunogenicity of these tumor cells (Sun et al., 2018). This evidence concerns the gene CD274 and neoplasm.